Periodic Reporting for period 1 - EDVance (EDV2209 – a Paradigm shift in the treatment of stroke.)
Berichtszeitraum: 2022-01-01 bis 2022-12-31
The project is aimed at demonstrating the safety of EDV2209 in humans and to show how the drug can reduce brain damage after SAH. The drug holds a potential to be the first drug to reduce brain damage and help survivors back to a normal life. To achieve this, we need a successful outcome of the clinical trial and to identify a a competent CNS partner with sufficient financial, technical and commercial capacity. This will require a significant business development skills and efforts. We have therefore organized a BD committee where we systematically plan and execute the various commercial initiatives. We are also discussing with brokers and investment banks who can assist us in identifying the right partner(s) and secure an attractive license agreement, alternatively a trade sale of the company. We explore to extend the orphan drug designation to Japan where SAH is more prevalent than in Europe and the US. We are currently working on new inventions to strengthen our IP protection and increase the commercial potential. Furthermore, we have another early stage project (outside the scope of this project) based on the same biological rationale and with an intravenous administration to treat broader stroke indications. This project will further strengthen the relevance and the potential of Edvince. The project will be financed by private investors which requires a solid investor relation effort.